Nasal Drug Delivery

SNBL’s nasal drug delivery platform is a proprietary system consisting of powder carrier technology and delivery device technology.

Expertise in Nasal Delivery

3D Nasal Cast Model


Platform Technology

Proprietary Nasal Drug Delivery System

SNBL has developed a proprietary nasal drug delivery technology, μco™ System, consisting of a powder carrier technology (μco™ Carrier) designed for increased drug absorption through its muco-adhesive properties and a delivery device technology designed for simple use, and complete and consistent delivery of intranasal powder formulations.
Our technology can be applied to a wide range of drugs, including small molecules, peptides, and biologics. It can be utilized for improved systemic drug absorption, enhanced muco-immunity for a vaccine, or for enabling drug delivery to the brain through the olfactory area.

Platform Technology

The μco™ System is a nasal drug delivery platform comprised of powder carrier technology and delivery device technology.

Powder Formulation Technology
μco™ Carrier

  • Powder carrier
  • Use of safety-proven pharmaceutical additives (FDA GRAS*)
  • Excellent safety profile in clinical trials in more than 150 subjects
  • Compatibility with the mucosal membrane
  • Muco-adhesive
  • Versatility of application to a wide range of drugs
  • Increased stability of formulation at room temperature

*GRAS: Generally Recognized as Safe: The U.S. Food and Drug Administration (FDA) designation that a chemical or substance added to food is generally recognized to be safe.

Delivery Device Technology

  • Single-use, disposable
  • Self-administration or by caregiver
  • Ergonomic design
  • Simple operation and easy to use
  • Complete and consistent delivery

Special Analyses for Nasal Drug Delivery System

Special analyses for the development of our nasal drug delivery technology

  • Primary particle size
  • Secondary particle size
  • Aerodynamic particle size
  • Plume geometry
  • Spray pattern
  • Nasal delivery devices for animal
  • Distribution analysis with human nasal cavity cast model
  • Distribution analysis with non-human primate nasal cavity model



  • Mizutani A, et al. Indirect SPECT Imaging Evaluation for Possible Nose-to-Brain Drug Delivery Using a Compound with Poor Blood-Brain Barrier Permeability in Mice. Pharmaceutics. 2022 May 10;14(5):1026.
  • Torikai Y, et al. Evaluation of Systemic and Mucosal Immune Responses Induced by a Nasal Powder Delivery System in Conjunction with an OVA Antigen in Cynomolgus Monkeys. J Pharm Sci. 2021 May;110(5):2038-2046.
  • Albrecht D, et al. A Phase1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects. Headache. 2020;0: 1-12
  • Milewski M,et al. Rapid Absorption of Dry-Powder Intranasal Oxytocin. Pharm Res. 2016;33: 1936-1944
  • Haruta S. PAIN MANAGEMENT - Rapid Action Therapy in Pain Relief: Potential for Nasal Delivery Systems. Drug Development and Delivery Magazine. July/August 2013 Issue
  • Haruta S. INTERVIEW - SNBL, Ltd.: Innovation in Drug Delivery Enabled Through a Unique Business Model. Drug Development and Delivery Magazine. May 2013 Issue
  • Haruta S. A Nasal Delivery Solution to the Challenges in Biotherapeutic Delivery. ONdrugDelivery Magazine. December 2012 Issue
  • Haruta S. How Nasal Delivery Can Meet the Changing Needs of Patients & the Drug Development Industry. ONdrugDelivery Magazine. November 2012 Issue
  • Haruta S. Special CRO Services Generated through R&D of Proprietary Nasal Delivery System. ONdrugDelivery Magazine. September 2012 Issue
  • Haruta S. ADVANCED DELIVERY DEVICES - Meeting the Needs of Nasal Delivery Devices for Powder Formulations. Drug Development and Delivery Magazine. June 2012 Issue
  • Haruta S. Achieving the Potential of Nasal Drug Delivery. ONdrugDelivery Magazine. April 2012 Issue